Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 6/20 | 0.32 |
| ▸ | GAA | P10253 | 6/20 | 0.32 |
| ▸ | SI | P14410 | 6/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 6/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6953767 | 0.77 | IMPDH2 (0.35) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL558333 | 0.75 | FFAR1 (0.32) | GPR84MGAMGAASIMGAM2 | |
| SCHEMBL558395 | 0.75 | NOS1 (0.42) | MAP2K4GPR84CYP1A2CYP2A6GAA | |
| SCHEMBL395374 | 0.75 | GAA (0.33) | GAAALDH1A1TSHRNPC1HPGD | |
| SCHEMBL7258404 | 0.75 | GABRA1 (0.38) | ALDH1A1DAO | |
| SCHEMBL3326167 | 0.72 | CYP1A2 (0.43) | CYP1A2GAAALDH1A1DAOHPGD | |
| SCHEMBL2353932 | 0.71 | METAP2 (0.47) | MAPK1CYP1A2CYP2A6GAAALDH1A1 | |
| SCHEMBL558190 | 0.71 | AXL (0.47) | KIF11SMN1; SMN2NPSR1 | |
| SCHEMBL315924 | 0.69 | KDM4E (0.50) | MAPK1MAP2K4MAPK6CYP1A2GAA | |
| SCHEMBL647458 | 0.68 | NOS1 (0.50) | MAPK1CYP1A2MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024121013-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-06-13 | — | — | WO | claimed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| WO-2024009215-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-11 | — | — | WO | claimed |
| CN-116234546-A | GPX4 inhibitors, pharmaceutical compositions thereof and their use in the treatment of GPX4 mediated diseases | 嘉兴优博生物技术有限公司 | 2023-06-06 | — | — | CN | claimed |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-06-01 | — | — | US | claimed |
| US-11225482-B2 | Dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2022-01-18 | — | — | US | claimed |
| EP-3927705-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1st Biotherapeutics, Inc. (KR) | 2021-12-29 | — | — | EP | claimed |
| EP-3927706-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF PROLIFERATIVE DISORDERS | 1st Biotherapeutics, Inc. (KR) | 2021-12-29 | — | — | EP | claimed |
| US-20210347774-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2021-11-11 | — | — | US | claimed |
| CN-113454082-A | Imidazopyridinyl compounds and their use for the treatment of neurodegenerative diseases | 第一生物治疗股份有限公司 | 2021-09-28 | — | — | CN | claimed |
| WO-2011163330-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-29 | — | — | WO | claimed |
| WO-2011140442-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-11-10 | — | — | WO | claimed |
| EP-2231602-A1 | GAMMA SECRETASE MODULATORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | claimed |
| EP-2203482-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | Bridgestone Corporation (JP) | 2010-07-07 | — | — | EP | claimed |
| WO-2009075874-A1 | GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | claimed |
| WO-2009051702-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2009-04-23 | — | — | WO | claimed |
| WO-2009051700-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION (US) | 2009-04-23 | — | — | WO | claimed |
| EP-1863771-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | Transtech Pharma, Inc. (US) | 2007-12-12 | — | — | EP | claimed |
| WO-2006099379-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2006-09-21 | — | — | WO | claimed |
| US-3998803-A | TEXTILES | FIDELITY UNION TRUST COMPANY, EXECUTIVE TRUSTEE UNDER THE SANDOZ TRUST (US) | 1976-12-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225482-B2 | Dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | DPYD, HAVCR2, QDPR | MAPK1 2023/4885MAP2K4 4075/4885MAPKAPK2 2716/4885 |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | CLK1, CLK2, CLK3 | MAPK1 268/4885MAP2K4 127/4885MAPKAPK2 109/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | MAPK1 513/4885MAP2K4 4220/4885MAPKAPK2 209/4885 |
| US-20210347774-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | MAPK1 880/4885MAP2K4 2935/4885MAPKAPK2 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.